Optimising Spirometry Endpoints in Clinical Trials

Optimising spiro CT (1)

Spirometry remains one of the most widely used pulmonary function tests in respiratory clinical trials, underpinning primary and secondary endpoints across a broad range of indications.

However, applying standardised quality assurance (QA) criteria uniformly across diverse patient populations may inadvertently introduce variability, exclude valuable data, and impact trial outcomes.

In this expert-led webinar, Grant Sowman, VP Clinical Services at Vitalograph, and Holly Wilson, Registered Pulmonary Function Technologist (RPFT) explore how a disease-specific approach to spirometry quality assurance can help optimise endpoint reliability while maintaining adherence to ATS/ERS 2019 standards.

Drawing on real-world clinical trial experience and practical case examples, this session examines the limitations of a one-size-fits-all QA framework and highlights how disease physiology can influence a patient's ability to meet spirometry acceptability criteria.

Attendees will gain insights into common objective and subjective QA errors, the role of expert over-reading, and strategies for balancing automated review with clinical judgement.

Whether you are involved in clinical trial study design, site management, pulmonary function testing, data review, or endpoint analysis, this webinar will provide practical strategies for improving spirometry data quality and reducing unnecessary variability in respiratory clinical trials, such as through tailored coaching, over-reading, and disease-specific QA frameworks

This webinar is ideal for sponsors, CROs, clinical trial site staff, respiratory physiologists, pulmonary function technologists, and anyone involved in the collection, review, or interpretation of spirometry endpoints in clinical research.

Originally broadcast on 01 September 2026.

Missed the live showing?

Catch with the webinar replay. Available until 20 October 2026.

Learning Objectives

Attending this webinar will support you to better:

  1. Interpret the ATS-ERS 2019 spirometry QA criteria in the context of clinical trial endpoints. ​

  2. Evaluate how disease-specific factors influence spirometry quality and endpoint reliability.

  3. Assess if there are limitations of uniform QA application across respiratory indications.

  4. Apply disease-specific considerations to improve spirometry QA practices in trials.

Presented By
Grant Sowman and Holly Wilson
About the Presenter

Grant Sowman is Vice President of Clinical Services at Vitalograph and a respiratory physiologist with over 20 years of experience in pulmonary function testing and respiratory clinical trials. He specialises in respiratory endpoint optimisation, quality assurance, and clinical trial oversight.

Holly Wilson, RPFT, is a Pulmonary Function Technologist with more than 30 years of experience in respiratory diagnostics and clinical trial pulmonary function testing. Her expertise includes patient coaching, test quality assessment, and operational delivery of respiratory endpoints in global clinical studies.